Literature DB >> 34319159

IFITM Proteins That Restrict the Early Stages of Respiratory Virus Infection Do Not Influence Late-Stage Replication.

Tina Meischel1, Svenja Fritzlar1, Fernando Villalon-Letelier1, Melkamu B Tessema1, Andrew G Brooks1, Patrick C Reading1,2, Sarah L Londrigan1.   

Abstract

Interferon-induced transmembrane (IFITM) proteins inhibit a broad range of enveloped viruses by blocking entry into host cells. We used an inducible overexpression system to investigate if IFITM1, IFITM2, and IFITM3 could modulate early and/or late stages of influenza A virus (IAV) or parainfluenza virus 3 (PIV-3) infection in human A549 airway epithelial cells. IAV and PIV-3 represent respiratory viruses which utilize distinct cellular entry pathways. We verify entry by endocytosis for IAV, whereas PIV-3 infection was consistent with fusion at the plasma membrane. Following induction prior to infection, all three IFITM proteins restricted the percentage of IAV-infected cells at 8 hours postinfection. In contrast, prior induction of IFITM1 and IFITM2 did not inhibit PIV-3 infection, although a modest reduction was observed with IFITM3. Small interfering RNA (siRNA)-mediated knockdown of endogenous IFITM1, IFITM2, and IFITM3 expression, in the presence or absence of pretreatment with type I interferon, resulted in increased IAV, but not PIV-3, infection. This finding suggests that while all three IFITMs display antiviral activity against IAV, they do not restrict the early stages of PIV-3 infection. IAV and PIV-3 infection culminates in viral egress through budding at the plasma membrane. Inducible expression of IFITM1, IFITM2, or IFITM3 immediately after infection did not impact titers of infectious virus released from IAV- or PIV-3-infected cells. Our findings show that IFITM proteins differentially restrict the early stages of infection of two respiratory viruses with distinct cellular entry pathways but do not influence the late stages of replication for either virus. IMPORTANCE Interferon-induced transmembrane (IFITM) proteins restrict the initial stages of infection for several respiratory viruses; however, their potential to modulate the later stages of virus replication has not been explored. In this study, we highlight the utility of an inducible overexpression system to assess the impact of IFITM proteins on either early- or late-stage replication of two respiratory viruses. We demonstrate antiviral activity by IFITM1, IFITM2, and IFITM3 against influenza A virus (IAV) but not parainfluenza virus 3 (PIV-3) during the early stages of cellular infection. Furthermore, IFITM induction following IAV or PIV-3 infection does not restrict the late stages of replication of either virus. Our findings show that IFITM proteins can differentially restrict the early stages of infection of two viruses with distinct cellular entry pathways and yet do not influence the late stages of replication for either virus.

Entities:  

Keywords:  IFITM; host restriction factors; influenza; parainfluenza virus

Mesh:

Substances:

Year:  2021        PMID: 34319159      PMCID: PMC8475524          DOI: 10.1128/JVI.00837-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections.

Authors:  Dong Jiang; Jessica M Weidner; Min Qing; Xiao-Ben Pan; Haitao Guo; Chunxiao Xu; Xianchao Zhang; Alex Birk; Jinhong Chang; Pei-Yong Shi; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity.

Authors:  Jocelyn C Hach; Temet McMichael; Nicholas M Chesarino; Jacob S Yount
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.

Authors:  Matteo Porotto; Samantha G Palmer; Laura M Palermo; Anne Moscona
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

4.  IFITM3 Restricts Human Metapneumovirus Infection.

Authors:  Temet M McMichael; Yu Zhang; Adam D Kenney; Lizhi Zhang; Ashley Zani; Mijia Lu; Mahesh Chemudupati; Jianrong Li; Jacob S Yount
Journal:  J Infect Dis       Date:  2018-10-05       Impact factor: 5.226

Review 5.  Viral entry mechanisms: the increasing diversity of paramyxovirus entry.

Authors:  Everett C Smith; Andreea Popa; Andres Chang; Cyril Masante; Rebecca Ellis Dutch
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

6.  Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin.

Authors:  E M Anders; C A Hartley; P C Reading; R A Ezekowitz
Journal:  J Gen Virol       Date:  1994-03       Impact factor: 3.891

Review 7.  Entry of influenza A virus: host factors and antiviral targets.

Authors:  Thomas O Edinger; Marie O Pohl; Silke Stertz
Journal:  J Gen Virol       Date:  2013-11-13       Impact factor: 3.891

Review 8.  Paramyxovirus fusion and entry: multiple paths to a common end.

Authors:  Andres Chang; Rebecca E Dutch
Journal:  Viruses       Date:  2012-04-19       Impact factor: 5.048

9.  IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread.

Authors:  Alex A Compton; Timothée Bruel; Françoise Porrot; Adeline Mallet; Martin Sachse; Marine Euvrard; Chen Liang; Nicoletta Casartelli; Olivier Schwartz
Journal:  Cell Host Microbe       Date:  2014-11-26       Impact factor: 21.023

Review 10.  Paramyxovirus glycoprotein incorporation, assembly and budding: a three way dance for infectious particle production.

Authors:  Farah El Najjar; Anthony P Schmitt; Rebecca Ellis Dutch
Journal:  Viruses       Date:  2014-08-07       Impact factor: 5.048

View more
  6 in total

1.  Mouse Mx1 Inhibits Herpes Simplex Virus Type 1 Genomic Replication and Late Gene Expression In Vitro and Prevents Lesion Formation in the Mouse Zosteriform Model.

Authors:  Melkamu B Tessema; Rubaiyea Farrukee; Christopher E Andoniou; Mariapia A Degli-Esposti; Clare V Oates; James B Barnes; Linda M Wakim; Andrew G Brooks; Sarah L Londrigan; Patrick C Reading
Journal:  J Virol       Date:  2022-05-31       Impact factor: 6.549

Review 2.  Positive Regulation of the Antiviral Activity of Interferon-Induced Transmembrane Protein 3 by S-Palmitoylation.

Authors:  Shubo Wen; Yang Song; Chang Li; Ningyi Jin; Jingbo Zhai; Huijun Lu
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

3.  Differential Transcriptomics Analysis of IPEC-J2 Cells Single or Coinfected With Porcine Epidemic Diarrhea Virus and Transmissible Gastroenteritis Virus.

Authors:  Lina Song; Jing Chen; Pengfei Hao; Yuhang Jiang; Wang Xu; Letian Li; Si Chen; Zihan Gao; Ningyi Jin; Linzhu Ren; Chang Li
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

4.  Expression of a Functional Mx1 Protein Is Essential for the Ability of RIG-I Agonist Prophylaxis to Provide Potent and Long-Lasting Protection in a Mouse Model of Influenza A Virus Infection.

Authors:  Lara S U Schwab; Fernando Villalón-Letelier; Melkamu B Tessema; Sarah L Londrigan; Andrew G Brooks; Aeron Hurt; Christoph Coch; Thomas Zillinger; Gunther Hartmann; Patrick C Reading
Journal:  Viruses       Date:  2022-07-15       Impact factor: 5.818

5.  Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.

Authors:  Lynette Miroslava Pacheco-Hernández; Jazmín Ariadna Ramírez-Noyola; Itzel Alejandra Gómez-García; Sergio Ignacio-Cortés; Joaquín Zúñiga; José Alberto Choreño-Parra
Journal:  J Interferon Cytokine Res       Date:  2022-06-07       Impact factor: 3.657

6.  Differential Leukocyte Expression of IFITM1 and IFITM3 in Patients with Severe Pandemic Influenza A(H1N1) and COVID-19.

Authors:  Nora E Regino-Zamarripa; Gustavo Ramírez-Martínez; Luis Armando Jiménez-Álvarez; Alfredo Cruz-Lagunas; Itzel Alejandra Gómez-García; Sergio Ignacio-Cortés; José Eduardo Márquez-García; Lynette Miroslava Pacheco-Hernández; Jazmín Ariadna Ramírez-Noyola; Rodrigo Barquera; Criselda Mendoza-Milla; Cesar Luna-Rivero; José Guillermo Domínguez-Cherit; Remedios Ramírez-Rangel; Tatiana Sofía Rodríguez-Reyna; Carmen M Hernández-Cárdenas; José Alberto Choreño-Parra; Gloria León-Ávila; Joaquín Zúñiga
Journal:  J Interferon Cytokine Res       Date:  2022-06-14       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.